JP6173850B2 - Muscle bulking agent, muscle bulking agent when used together with exercise, and food and drink for muscle weight gain - Google Patents

Description

  The present invention relates to a muscle bulking agent and a muscle bulking agent used in combination with exercise.

It is generally known that muscle mass decreases and muscle strength decreases with age. Since muscles are the basis of daily activities such as standing, walking, and maintaining posture, a decrease in muscle mass or a decrease in muscle strength significantly reduces the quality of life.
Aerobic exercise such as walking is highly effective in maintaining and strengthening the functions of the circulatory system such as the heart and lungs, but is not very effective in increasing muscle mass and strength. In order to increase muscle mass and strength, specific exercises such as muscle training called resistance exercise and weight training are required. In particular, high-intensity exercise of about 70% of the maximum lifting weight is effective. However, a high intensity exercise condition of 70% of the maximum lifting weight has a very high risk of injury when targeting the elderly or middle-aged and elderly with a disease.

For example, the use of growth hormone has been studied as a method for strengthening muscles without exercising at high intensity, but growth hormone has been studied for doping problems, carcinogenicity, hypertension, liver damage, testicular atrophy, amenorrhea, etc. It has side effects and it is not preferable to take it continuously for a long time.
In addition, as dietary therapy for strengthening muscles, intake of proteins and amino acids, which are muscle materials, is encouraged, but the clear effect is weak and there is a great difference between individuals.
Further, muscle bulking agents containing ornithine or a salt thereof as an active ingredient (see Patent Document 1), muscle bulking agents containing licorice hydrophobic extract as an active ingredient (see Patent Document 2), and the like have been proposed. However, none of these proposed muscle bulking agents are sufficiently satisfactory in terms of the muscle weight gain effect.

  In addition, the applicant of the present application has previously proposed a muscle atrophy inhibitor containing ginseng ginseng as an active ingredient (see Patent Document 3). Panaxdiol and panaxatriol are contained only in a slight amount in Panaceae ginseng itself, and furthermore, in the water extract described in Patent Document 3 as having a high muscular atrophy inhibitory effect and preferable, Panaxadiol and panaxatriol, which are hydrophobic, are not included. This proposal effectively suppresses muscle atrophy, but does not have an effect of increasing muscle mass.

  Therefore, there is a strong need to provide a muscle extender that does not require a special exercise load such as resistance exercise, has a low risk of injury or side effects, and can effectively increase muscle mass, and a muscle extender when combined with exercise. This is the current situation.

International Publication No. 2007/077995 Pamphlet JP 2012-193157 A JP 2008-179620 A

  An object of the present invention is to solve the above-described problems and achieve the following objects. That is, since the present invention does not require a special exercise load such as resistance exercise, there is little risk of injury or side effect, and a muscle extender capable of effectively increasing muscle mass and a muscle extender for combined use with exercise. The purpose is to provide.

The muscle bulking agent of the present invention as a means for solving the above-mentioned problems contains at least one of panaxatriol and panaxadiol.
Further, the muscle bulking agent used in combination with exercise of the present invention contains at least one of panaxatriol and panaxadiol.

  According to the present invention, the conventional problems can be solved, the object can be achieved, and a special exercise load such as resistance exercise is not required. It is possible to provide a muscle bulking agent capable of increasing the weight and a muscle bulking agent used in combination with exercise.

FIG. 1 is a graph showing the measurement results of the weight of the scissors muscle in Experimental Example 1. FIG. 2 is a graph showing measurement results of long finger extensor weight in Experimental Example 1. FIG. 3 is a graph showing the measurement results of the weight of the scuffed muscle in Experimental Example 2. FIG. 4 is a graph showing the measurement results of the long finger extensor weight in Experimental Example 2. FIG. 5 is a graph showing the results of changes in the expression level of skeletal muscle constituent factors by addition of panaxatriol (PT) or panaxadiol (PD) in Experimental Example 3.

(Muscle bulking agent and muscle bulking agent when combined with exercise)
The muscle bulking agent of the present invention contains at least one of panaxatriol and panaxadiol, and further contains other components as necessary.
The muscle bulking agent used in combination with exercise of the present invention contains at least one of panaxatriol and panaxadiol, and further contains other components as necessary.

<When combined with exercise>
The term “when exercising with exercise” means taking a muscle bulking agent while exercising, and the term “exercise” refers to exercise of walking to light running, and 40% to 70% VO ₂ max. It means exercise intensity of 3 to 6 mets. The frequency is preferably 3 to 5 times a week, and the time is preferably 15 to 60 minutes.
・ Reference 1: How to perceive exercise intensity (Akira Ito: Illustrated: Introduction to Exercise Physiology, p.129, Ishiyaku Shuppan Publishing, 1990), http://www-user.yokohama-cu.ac.jp/~sport /menu/staff/tamaki/edu/training.html
・ Reference 2: Exercise Guidelines 2006 for Health Promotion (Ministry of Health, Labor and Welfare: Exercise Guide, p.7, 2006), http://www.mhlw.go.jp/bunya/kenkou/undou01/pdf/data.pdf

<Panaxatriol (PT) and Panaxadiol (PD)>
The panaxatriol and the panaxadiol are compounds belonging to danmaran triterpenes.
The panaxatriol and the panaxadiol are those in which sugar is removed from a plant-derived saponin (glycoside) to form an aglycon body.
There is no restriction | limiting in particular as said plant, Although it can select suitably according to the objective, Araliaceae ginseng is preferable and, among these, the ginseng is more preferable.
The saponin derived from the ginseng ginseng is not particularly limited and may be appropriately selected depending on the intended purpose. For example, ginsenoside-Rg ₁ , notoginsenoside-R ₁ , ginsenoside-Re, ginsenoside-Rb ₁ , ginsenoside- Rd, ginsenoside-Rc, etc. are mentioned.

-How to obtain-
The method for obtaining the panaxatriol and the panaxadiol is not particularly limited and may be appropriately selected depending on the intended purpose. For example, a method obtained by extracting from the calyx ginseng, Examples thereof include a method obtained by enzymatic fermentation, a method obtained by hydrolyzing the ginseng ginseng, a method obtained by synthesis, and the like. Commercial products can also be used.
There is no restriction | limiting in particular as the method obtained by said extraction, According to the objective, it can select suitably, For example, a supercritical extraction method, HPLC extraction method, etc. are mentioned.
Among these, the method obtained by hydrolysis is preferable, and the method obtained by acid hydrolysis is more preferable. Hydrolysis of the ginseng ginseng is advantageous in that the panaxatriol and the panaxadiol can be obtained efficiently, and an excellent muscle weight-increasing action and a muscle weight-increasing action in combination with exercise can be exhibited. .

  In addition, the araliaceae ginseng may be used as it is collected from nature. For example, it may be used after pretreatment appropriately combining washing, drying, cutting, crushing, pulverization and the like. . Among these, it is preferable to use a powdery ginseng as the Arcoceae ginseng because the panaxatriol and the panaxadiol can be efficiently obtained.

--Hydrolysis treatment--
There is no restriction | limiting in particular as the processing method of the said hydrolysis, According to the objective, it can select suitably, For example, the method etc. which make strong acid aqueous solution of a desired density | concentration act on the said Araliaceae ginseng are mentioned.
The strong acid aqueous solution is not particularly limited as long as it is an aqueous solution containing a strong acid, and can be appropriately selected according to the purpose, but an aqueous solution containing an inorganic acid such as hydrochloric acid, phosphoric acid, sulfuric acid, nitric acid is preferable, and hydrochloric acid An aqueous solution containing is more preferred.

There is no restriction | limiting in particular as a density | concentration of the acid in the said strong acid aqueous solution, Although it can select suitably according to the objective, 0.01 mol / L-4 mol / L are preferable, and 0.5 mol / L-3 mol / L are more preferable.
When the concentration of the acid is less than 0.01 mol / L, hydrolysis is insufficient, and there is a problem that the panaxatriol and the panaxadiol cannot be efficiently obtained, and when the concentration exceeds 4 mol / L. , Problems such as excessive hydrolysis and disadvantages in cost occur.
On the other hand, when the acid concentration is within the preferred range, it is advantageous in that the panaxatriol and the panaxadiol can be efficiently obtained by sufficient hydrolysis.

There is no restriction | limiting in particular as the usage-amount of the said strong acid aqueous solution, Although it can select suitably according to the objective, It is preferable to use a 2 times volume-20 times capacity | capacitance with respect to the said Araliaceae ginseng.
If the amount of the strong acid aqueous solution used is less than twice the capacity of the ginseng ginseng, the ginseng ginseng is not sufficiently soaked and the hydrolysis treatment becomes insufficient. There is a disadvantage in terms of cost.

--- Use of lower alcohols ---
The hydrolysis treatment is preferably performed in the presence of a lower alcohol.
By using the lower alcohol, it is possible to improve the affinity between the ginseng ginseng and the strong acid aqueous solution, and to proceed the hydrolysis efficiently.
There is no restriction | limiting in particular as said lower alcohol, Although it can select suitably according to the objective, Methanol, ethanol, and propanol are preferable and ethanol is more preferable from a safety point.

The amount of the lower alcohol used is not particularly limited and may be appropriately selected depending on the intended purpose. It is preferably 1% by volume to 80% by volume with respect to the total amount of the hydrolyzed liquid, and 10% by volume to 50% by volume. Is more preferable, and 20% by volume to 40% by volume is still more preferable.
When the amount of the lower alcohol used is less than 1% by volume with respect to the total amount of the hydrolyzed solution, the panaxatriol and the panaxadiol may not be obtained efficiently, and exceeds 80% by volume. In other words, the panaxatriol and the panaxadiol cannot be efficiently obtained, and the cost is disadvantageous.
On the other hand, when the amount of the lower alcohol used is within the preferred range, it is advantageous in that the panaxatriol and the panaxadiol can be obtained efficiently.
The “total amount of hydrolyzed liquid” refers to the total amount of the reaction liquid including the strong acid aqueous solution and the lower alcohol.

--- Total amount of hydrolyzed liquid ---
The total amount of the reaction solution (the total amount of the hydrolyzed solution) including the strong acid aqueous solution and the lower alcohol is not particularly limited and may be appropriately selected depending on the intended purpose. A capacity of ˜20 times is preferred.
When the total amount of the reaction solution is less than twice the volume of the carrot ginseng, the carrot carrot may not be sufficiently immersed and the hydrolysis treatment may be insufficient. , It may be disadvantageous in terms of cost.

--- Hydrolysis treatment temperature ---
There is no restriction | limiting in particular as processing temperature in the said hydrolysis process, Although it can select suitably according to the objective, 60 to 100 degreeC is preferable and 70 to 90 degreeC is more preferable.
If the treatment temperature is less than 60 ° C, hydrolysis may be insufficient, and the panaxatriol and panaxadiol may not be obtained efficiently. Equipment is required, which may be disadvantageous in terms of cost.
On the other hand, when the treatment temperature is within the preferable range, it is advantageous in that the panaxatriol and the panaxadiol can be efficiently obtained.

--- Hydrolysis treatment time ---
There is no restriction | limiting in particular as processing time in the said hydrolysis process, Although it can select suitably according to the objective, 30 minutes-24 hours are preferable, and 2 hours-8 hours are more preferable.
If the treatment time is less than 30 minutes, hydrolysis may be insufficient and the protopanaxadiol and panaxadiol may not be obtained efficiently. If the treatment time exceeds 24 hours, the reaction proceeds. It may be too costly and disadvantageous in terms of cost.
On the other hand, when the treatment time is within the preferable range, it is advantageous in that the protopanaxadiol and the panaxadiol can be obtained efficiently.

--- Neutralization treatment--
After the hydrolysis treatment, it is preferable to neutralize the obtained solution after the hydrolysis treatment. There is no restriction | limiting in particular as the method of neutralizing, It can carry out by a well-known method, for example, the method of adding strong base aqueous solution, such as sodium hydroxide and potassium hydroxide, to the liquid after the said hydrolysis process suitably, etc. Is mentioned. In addition, there is no restriction | limiting in particular as pH after the said neutralization, Although it can select suitably according to the objective, pH 5-pH8 are preferable.

-Filtration treatment-
The liquid after the hydrolysis treatment after the neutralization step is preferably filtered and separated into a filtrate and a residue, and the residue is more preferably used. There is no restriction | limiting in particular as the method of filtering, It can carry out by a well-known method. After filtration, washing with water may be repeated until there is no more salt.

--- Hydrofiltration ---
When the lower alcohol is not used in the hydrolysis treatment step, the filtration treatment can be performed as it is after neutralization. However, when the lower alcohol is used, before the filtration, the panaxatriol and the panaki are used. In order to promote the residue of sadiol in the residue, it is preferable to add water to lower the lower alcohol concentration in the liquid after the hydrolysis treatment.
The amount of water to be added in this case is not particularly limited and can be appropriately selected according to the purpose. The larger the amount, the more preferable, but the lower alcohol concentration in the liquid after hydrolysis treatment is 0.05% by volume or more. It is more preferable to add so that it may become 50 volume% or less, It is still more preferable to add so that it may become 30 volume% or less, It is especially preferable to add so that it may become 10 volume% or less.
When subjected to filtration while the lower alcohol concentration in the liquid after the hydrolysis treatment exceeds 50% by volume, the panaxatriol and the panaxadiol are dissolved in the lower alcohol and discharged as a filtrate, This is disadvantageous in that the content in the residue is reduced.
On the other hand, if the lower alcohol concentration in the liquid after the hydrolysis treatment is within the more preferable range, it is advantageous in that the content of the panaxatriol and the panaxadiol in the residue can be further increased. is there.

--- Drying process--
The residue after the filtration step may be used as it is as the panaxatriol and panaxadiol, or may be used after drying.
There is no restriction | limiting in particular as the method of drying, It can carry out by a well-known method, For example, a freeze-drying method, ventilation drying method, heat drying method, reduced pressure drying method etc. are mentioned.

-Content-
The content of the panaxatriol and the panaxadiol contained in the muscle bulking agent or the muscle bulking agent used in combination with exercise is not particularly limited, and is within the range not impairing the effects of the present invention. It can be selected as appropriate according to the conditions. Further, the muscle bulking agent or the muscle bulking agent used in combination with exercise may be at least one of the panaxatriol and the panaxadiol.

<Other ingredients>
The other component is not particularly limited and may be appropriately selected depending on the intended purpose. For example, the muscle bulking agent or the muscle bulking agent used in combination with exercise from among pharmacologically acceptable carriers. It can be appropriately selected depending on the shape and the like, and examples thereof include ethanol, water, starch and the like. Moreover, when utilizing the said muscle bulking agent or the muscle bulking agent at the time of exercise together for the food / beverage products mentioned later, as said other component, various auxiliary raw materials or additives are mentioned, for example. There is no restriction | limiting in particular also as content of the said other component, According to the objective, it can select suitably.

<Dosage form>
The dosage form of the muscle bulking agent or the muscle bulking agent used in combination with exercise is not particularly limited and may be appropriately selected depending on the intended purpose. Examples thereof include oral solid preparations, oral semisolid preparations, and oral liquid preparations. Can be mentioned. Among these, oral solid preparations are preferable.

-Oral solid agent-
The oral solid preparation is not particularly limited and may be appropriately selected depending on the intended purpose. For example, tablets, chewable tablets, effervescent tablets, orally disintegrating tablets, troches, drops, hard capsules, soft capsules Agents, granules, powders, pills, dry syrups, soaking agents and the like. Among these, capsules are preferable.
Examples of the capsule include No. 1 S. Rock, cap: XKZ HP BROWN5, body: XKZ HP BROWN5 manufactured by Clio Caps Co., Ltd., and the like.

-Oral semi-solid formulation-
There is no restriction | limiting in particular as said oral semi-solid preparation, According to the objective, it can select suitably, For example, a licking agent, a chewing gum agent, a whipping agent, a jelly agent etc. are mentioned.

-Oral solution-
There is no restriction | limiting in particular as said oral liquid agent, According to the objective, it can select suitably, For example, a syrup agent, a drink agent, a suspension agent, an alcoholic agent etc. are mentioned.

  There is no restriction | limiting in particular as a manufacturing method of the said sugar metabolism improving agent, According to dosage form etc., it can select suitably from well-known methods.

<Ingestion>
There are no particular restrictions on the method of taking the muscle bulking agent or the muscle bulking agent used in combination with exercise, the amount taken, the number of times taken, the time of taking, and the subject of intake, and can be appropriately selected according to the purpose.
There is no restriction | limiting in particular as said ingestion method, Although it can select suitably according to the objective, The method of ingesting orally is preferable at the point which is easy to continue since it can ingest easily.
The intake amount is not particularly limited and may be appropriately selected in consideration of various factors such as the age, weight, constitution, symptom, and presence / absence of administration of a drug containing another component as an active ingredient. However, the daily intake is preferably 4.5 mg to 50 mg, more preferably 9 mg to 27 mg. Within the preferable range, it is advantageous in that an excellent muscle weight increasing action and a muscle weight increasing action when combined with exercise can be exhibited.
The ingestion time is not particularly limited and can be appropriately selected depending on the purpose. The muscle weight-increasing agent or the muscle weight-increasing agent in combination with exercise may be taken before or after exercise. It does n’t matter if you are exercising.
In addition, in order to reduce the annoyance related to taking for users, the intake time should not be limited at the same time as meals or after meals, and even if it is not taken at the same time as meals, muscle increasing action or exercise combination However, if the form to be taken is a normal food product that can be taken without any trouble in the diet, The effect of increasing muscle mass is not different depending on the time of intake, and is not related to non-simultaneous intake.
The animal species to be ingested are those that are suitably applied to humans, but as long as their effects are exerted, animals other than humans (eg, mice, rats, hamsters, birds, dogs, Cats, sheep, goats, cows, pigs, monkeys, etc.).

<Use>
The muscle bulking agent and the muscle bulking agent used in combination with exercise may be used singly or in combination of two or more, and used in combination with a pharmaceutical comprising other ingredients as active ingredients. Also good. Further, the muscle bulking agent and the muscle bulking agent used in combination with exercise may be used in a state of being blended in a medicine containing other ingredients as active ingredients.

<Application>
The muscle bulking agent or the muscle bulking agent used together with exercise has an excellent muscle bulking action and a muscle bulking action used together with exercise, and therefore can be suitably used for foods and drinks described later.
The muscle bulking agent of the present invention can exert a muscle weight gain effect without performing the specific exercise conventionally required for muscle weight gain. Therefore, even when administered to subjects who are difficult to exercise due to exercise, such as bedridden sick people, patients with injuries or illnesses that need to rest for a certain period of time, elderly people who are difficult to exercise intensely, muscle mass can be increased or maintained. Expected to have bedridden prevention effect.
Moreover, the muscle bulking agent at the time of exercise combined use of the present invention can also exert a muscle weight gain effect by being administered in combination with daily exercise with exercise intensity of 3 to 6 mets. Daily exercises here include not only jogging, flexible gymnastics, esthetic gymnastics, and other hobby sports, but also light work such as commuting, work and housework.
In addition, a preferable effect is acquired also by administering the muscle bulking agent at the time of exercise combined use of this invention in combination with the resistance exercise | movement conventionally made effective for muscle weight gain. The resistance exercise is an exercise performed by applying a certain load to the muscle, and the method of applying the load is not particularly limited. In addition to a barbell and a machine, an appropriate heavy object, water, an expander, and a rubber tube are used. Etc. can be used.

<Food &Drink>
The food and drink used in the present invention contains the above-described muscle bulking agent or the muscle bulking agent used in combination with exercise, and further contains other components as necessary.
Here, the food and drink are those which are less likely to harm human health and are taken by oral or gastrointestinal administration in normal social life. It is not limited to the category of goods, etc., and means, for example, a wide range of foods that are taken orally, such as general foods, health foods, health functional foods, quasi drugs, and pharmaceuticals.

The blending amount of the muscle bulking agent in the food and drink and the muscle bulking agent at the time of exercise combined use is not particularly limited, and may be appropriately determined depending on the type of the food or drink to be used within the range not impairing the effects of the present invention. Can be blended.
The food or drink may contain only the muscle bulking agent and the muscle bulking agent used together with exercise, and the food or drink is the muscle bulking agent and the muscle bulking agent used together with exercise. May be.

-Types of food and drink-
There is no restriction | limiting in particular as said kind of food / beverage products, According to the objective, it can select suitably, For example, drinks, such as a soft drink, a carbonated drink, a nutritive drink, a fruit drink, a lactic acid drink; Ice cream, ice sherbet, Frozen confectionery such as shaved ice; noodles such as buckwheat, udon, harusame, gyoza peel, sushi mai, Chinese noodles, instant noodles; rice cake, candy, gum, chocolate, tablet confectionery, snack confectionery, biscuits, jelly, jam, cream, baked Confectionery such as confectionery and bread; crab, salmon, clams, tuna, sardines, shrimp, skipjack, mackerel, whale, oyster, saury, squid, red scallop, scallop, abalone, sea urchin, salmon roe, tocobushi, etc .; Processed fishery and livestock products such as sausages; dairy products such as processed milk and fermented milk; salad oil, tempura oil, margarine, ma Oils and processed oils such as nauses, shortenings, whipped creams, dressings; seasonings such as sauces and sauces; curry, stew, oyakodon, rice cakes, miscellaneous cooking, Chinese rice cakes, bowls, tempura, eel rice, hayashi rice, oden, Retort pouch foods such as Mabodorf, beef bowl, meat sauce, egg soup, omelet rice, dumplings, shumai, hamburger, meatballs; various forms of health foods, nutritional supplements, pharmaceuticals, quasi drugs, and the like.

<Other ingredients>
There is no restriction | limiting in particular as said other component, According to the objective, it can select suitably, For example, the auxiliary | assistant raw material or additive etc. which are normally used in manufacturing food-drinks are mentioned.
The auxiliary raw material or additive is not particularly limited and may be appropriately selected depending on the intended purpose. For example, glucose, fructose, sucrose, maltose, sorbitol, stevioside, rubusoside, corn syrup, lactose, citric acid , Tartaric acid, malic acid, succinic acid, lactic acid, L-ascorbic acid, dl-α-tocopherol, sodium erythorbate, glycerin, propylene glycol, glycerin fatty acid ester, polyglycerin fatty acid ester, sucrose fatty acid ester, sorbitan fatty acid ester, Arabia Examples include gum, carrageenan, casein, gelatin, pectin, agar, vitamin Bs, nicotinic acid amide, calcium pantothenate, amino acids, calcium salts, pigments, fragrances, preservatives and the like.
There is no restriction | limiting in particular as content of the said other component, According to the objective, it can select suitably.

  EXAMPLES Hereinafter, although an Example is given and this invention is demonstrated in detail, this invention is not limited to these Examples at all.

<Exercise intensity>
The exercise intensity is an exercise of walking to light running, and corresponds to 40% to 70% VO ₂ max, 3 to 6 mets. The frequency is preferably 3 to 5 times a week, and the time is preferably 15 to 60 minutes.
The exercise imposed on the mouse in the following examples was “15 m / min, 45 min, tilt angle 0 °, 5 days / week, and treadmill running exercise for 38 days” corresponding to the exercise intensity in humans.
Reference 1: How to perceive exercise intensity (Ito Akira: Illustrated: Introduction to Exercise Physiology, p.129, Ishiyaku Shuppan Publishing, 1990), http: // www-user. yokohama-cu. ac. jp / ˜sport / menu / stuff / tamaki / edu / training. html
Reference 2: Exercise Guidelines 2006 for Health Promotion (Ministry of Health, Labor and Welfare: Exercise Guide, p. 7, 2006), http: // www. mhlw. go. jp / bunya / kenkou / undou01 / pdf / data. pdf

(Production Example 1)
<Nanata Participant Engineering Powder (Acid Treatment)>
1 kg of ginseng powder (manufactured by Matsuura Pharmaceutical Co., Ltd.) is suspended in 10 L of a 25 wt% aqueous ethanol solution containing 5.9 wt% hydrochloric acid (2 mol / L hydrochloric acid) and reacted at 70 ° C. for 6 hours with slow stirring. I let you. Subsequently, after cooling this reaction liquid on ice, 5 mol / L sodium hydroxide aqueous solution was added and it adjusted to pH 7.0. Next, the pH-adjusted solution was diluted 10-fold with distilled water, suction filtered, and separated into a filtrate and a residue. The obtained residue was freeze-dried to obtain 180 g of Tanashi Ninjin Participant Powder.
The contents of panaxatriol (PT) and panaxadiol (PD) in the obtained Nanata Participant's powder were analyzed and measured by the following method. The content of PT was 6.1% by mass. The PD content was 4.6% by mass.

<Analysis of PT and PD>
About 0.1 g of Tanashi Ninjin Participation Powder was precisely weighed, added with about 8 mL of ethanol (purity 99.5% by volume), and suspended for 15 minutes using an ultrasonic bath. After centrifugation at about 700 × g for 10 minutes, ethanol (purity 99.5% by volume) was added to the supernatant to make exactly 10 mL. This liquid was measured by gas chromatography under the following conditions. The retention time of PT under the following conditions was about 29 minutes, and the retention time of PD was about 18 minutes.
[Analysis conditions]
Gas chromatograph: GC353B (GL Science Co., Ltd.)
Detector: Hydrogen flame ionization detector (FID)
Injection method: Split injection method (split ratio 1:50)
Column: DB-17MS (length 30 m, inner diameter 0.25 mm, film thickness 0.25 μm, manufactured by Agilent Technologies)
Column temperature: Initial temperature: 310 ° C
Initial temperature holding time: 20 minutes
Temperature increase rate: 10 ° C / min
Achieving temperature: 320 ° C
Achieving temperature holding time: 14 minutes Carrier gas: Helium Flow rate: 1.5 mL / min Inlet temperature: 320 ° C
Detector temperature: 320 ° C
Injection volume: 1 μL

  Panaxatriol standard product (manufactured by LKT Laboratories) and panaxadiol standard product (manufactured by LKT Laboratories) were prepared to 1 mg / 1 mL, 0.5 mg / mL, and 0.1 mg / mL, respectively, and a calibration curve was prepared. A standard solution was prepared. The standard solution for calibration curve was measured by gas chromatography under the same conditions as described above using 1 μL each. Each peak area was measured, and a calibration curve was prepared from the peak area and concentration of each standard curve standard solution. Using this calibration curve, the contents of PT and PD in the Nanajin Participant's powder were measured.

<Panaxatriol, Panaxadiol>
An ethanol solution containing 3% by mass of the Nanajin Participant's powder was prepared. Next, after removing insolubles using filter paper, the solution is further concentrated 8 times using a rotary evaporator, and the concentrated solution is added to a glass column packed with silica gel (silica gel 60N, manufactured by Kanto Chemical Co., Inc.), Column fractionation was performed using chloroform: ethanol = 10: 1 (V / V) as an eluent. On normal phase TLC using chloroform: ethanol = 10: 1 (V / V) as a developing solvent, the fraction corresponding to an Rf value of 0.4 was concentrated to obtain highly pure panaxatriol (PT). It was. Further, the fraction corresponding to an Rf value of 0.6 was concentrated to obtain highly pure panaxadiol (PD).

(Experimental example 1)
<About the combined effect of panaxatriol (PT) and exercise>
〔Method〕
KKAy mice (CLEA Japan, 5-week-old male, 8 mice / group) were preliminarily raised for 5 days and acclimatized. (1) Control group (no exercise load), (2) PT group (no exercise load, PT 0.24 mass% mixed administration) (Example 1), (3) Exercise group (exercise) (4) Exercise + PT group (exercise load, PT 0.24 mass% mixed diet administration) (Example 2). The feed (CE-2, Nippon Claire) was given 5.5g per day so that it could be taken before and after exercise. In addition, water was freely consumed.
The treadmill running exercise was performed for 38 days under conditions of 15 m / min, 45 min, an inclination angle of 0 °, and 5 days / week. Thereafter, the weights of the hifuku muscle and the long finger extensor were measured. The results are shown in Tables 1-2 and FIGS. For statistical calculation, Student's t-test was used, and a significance level of less than 5% was regarded as a significant difference by two-sided test.

<Hifuku muscle weight>
Mean value ± standard error, n = 8, student't test (vs Control)
*: P <0.05

<Long finger extensor weight>
Mean value ± standard error, n = 8, student't test (vs Control)
*: P <0.05

〔result〕
From the results shown in Tables 1 and 2 and FIGS. 1 and 2, the exercise + PT group showed significantly higher weights of the hifuku and long extensor muscles, and it was difficult for the muscle mass to increase normally. Also, it was found that muscle mass increased. Furthermore, although no significant difference was observed in the PT administration group, the mean value of the muscle weight was higher than that in the control group, and it was thus found that the muscle mass was increased by taking PT. There are slow muscles that are mainly used during endurance exercise and fast muscles that are mainly used during instantaneous exercise. The hyfuku muscle is a mixture of slow and fast muscles, and the long finger extensor is a typical fast muscle. From these results, the synergistic effect of using PT and exercise in combination with the increase in fast muscle was particularly high.

(Experimental example 2)
<About combined effect of panaxadiol (PD) and exercise>
〔Method〕
KKAy mice (CLEA Japan, 5-week-old male, 8 mice / group) were preliminarily raised for 5 days and acclimatized. (1) Control group (no exercise load), (2) PD group (no exercise load, PD 0.24 mass% mixed administration) (Example 3), (3) Exercise group (exercise) (4) Exercise + PD group (with exercise load, PD 0.24 mass% mixed diet administration) (Example 4). The feed (CE-2, Nippon Claire) was given 5.5g per day so that it could be taken before and after exercise. In addition, water was freely consumed.
The treadmill running exercise was performed for 38 days under conditions of 15 m / min, 45 min, an inclination angle of 0 °, and 5 days / week. Thereafter, the weights of the hifuku muscle and the long finger extensor were measured. The results are shown in Tables 3 to 4 and FIGS. For statistical calculation, Student's t-test was used, and a significance level of less than 5% was regarded as a significant difference by two-sided test.
〔result〕

<Hifuku muscle weight>
Mean value ± standard error, n = 8, student't test (vs Control)
*: P <0.05

<Long finger extensor weight>
Mean value ± standard error, n = 8, student't test (vs Control)
*: P <0.05

  From the results shown in Tables 3 to 4 and FIGS. 3 to 4, compared to the control group, in the exercise + PD group, the weight of the hifuku and long extensor muscles is significantly higher, and the light exercise is usually less likely to increase Also, it was found that muscle mass increased. Furthermore, although there was no significant difference in the PD administration group, the average value of the muscle weight was higher than that in the control group, and it was thus found that the muscle mass was increased by ingesting PD. From these results, the synergistic effect by combining exercise and PD intake was particularly high for the increase in fast muscle.

(Experimental example 3)
<Effects of panaxatriol (PT) and panaxadiol (PD) on skeletal muscle cells>
〔Method〕
Rat skeletal muscle-derived cell line (L6 · C11) was purchased from European Collection of Cell Cultures (ECACC). L6 · C11 cells were cultured in a DMEM medium (Sigma-Aldrich) containing 1% fetal bovine serum (FBS) and 1% by mass streptomycin / penicillin in a 10 cm ² plate. Thereafter, cells were seeded on a 6-well plate coated with type I collagen, cultured for 3 days, and then replaced with a MEM medium (Nacalai Tesque) containing 2% by mass FBS and 1% by mass streptomycin / penicillin. Differentiated into myotubes by culturing for days. Then, 0.2 mass% BSA (manufactured by Sigma-Aldrich) and MEM medium (0.2 mass% BSA-MEM medium) containing mass% streptomycin / penicillin were replaced with Serum starvation. After 24 hours from the start of Serum starvation, the plate was washed 3 times with PBS, and then total RNA was collected using RNeasy mini Kit (Qiagen) according to the recommended protocol.
PT (10 μM) (Example 5), PD (10 μM) (Example 6), or solvent (DMSO: no addition group) was added 1 hour before the start of PBS washing. The cell culture and the treatment with the sample-added medium were performed at 37 ° C. and 5% CO ₂ . PT and PD need to be dissolved in an organic solvent because of their high hydrophobicity, and this time they were dissolved in DMSO. Using G GeneChip ^(R) 3 ′ IVT Express Kit (Affymetrix), aRNA (amplified RNA) was amplified using 500 ng of total RNA as a template according to the recommended protocol. The amplified aRNA was reacted with GeneChip® Rat Genome 230 2.0 Array (Affymetrix ⁾ according to the recommended protocol. In the GeneChip ^(R) Rat Genome 230 2.0 Array, 31,000 or more probe sets that bind only to aRNA amplified from specific RNA are arranged. The signal value of each probe set was measured using GeneChip ^(R) Scanner 3000 (Affymetrix) and GeneChip ^(R) Operating Software (Affymetrix). The results are shown in Table 5 and FIG.
As the amount of aRNA recognized by each probe set increases, the signal value of each probe set increases, and the amount of aRNA correlates with the amount of RNA serving as a template. That is, increase / decrease in the signal value of the probe set indicates increase / decrease in RNA serving as a template. The values in Table 5 and FIG. 5 are values obtained by dividing the signal value of the PT or PD added group of each probe set by the signal value of the non-added group, that is, the increase rate of the signal value of each probe set by adding PT or PD. Show. All samples were performed with n = 3, and the data variation was represented by standard error.
〔result〕

<Change in expression level of skeletal muscle constituent factor by PT or PD addition>

Amplified from mRNA of actin, myosin, troponin, and tropomyosin, which are proteins constituting sarcomeric sarcomere of skeletal muscle, from the signal value data of more than 31,000 probe sets obtained by DNA microarray analysis Probe set data that recognizes the aRNA was extracted.
From the results of Table 5 and FIG. 5, the signal value of the probe set that recognizes aRNA amplified from actin, myosin, troponin, and tropomyosin mRNA is increased in the PT and PD added groups compared to the non-added group. Was confirmed. Since an increase in the signal value of the probe set indicates an increase in mRNA, it was confirmed that PT and PD have an effect of increasing the amount of mRNA of the protein constituting the sarcomere of skeletal muscle.

As an aspect of this invention, the following are mentioned, for example.
<1> A muscle bulking agent characterized by containing at least one of panaxatriol and panaxadiol.
<2> A muscle bulking agent used in combination with exercise, characterized by containing at least one of panaxatriol and panaxadiol.
<3> The muscle bulking agent used in combination with exercise according to <2>, wherein the intensity of exercise used in combination is 3 to 6 Mets.
<4> The muscle bulking agent according to any one of <1> to <3>, which has an action of increasing at least one skeletal muscle sarcomeric component protein selected from actin, myosin, thrombomyosin, and thrombonin. .
<5> The muscle bulking agent according to any one of <1> to <3>, which has a gene expression enhancing action of at least one skeletal muscle sarcomere constituting protein selected from actin, myosin, thrombomyosin, and thrombonin. It is.
<6> At least one of panaxatriol and panaxadiol is the muscle bulking agent according to any one of the items <1> to <5>, which is contained in a strongly acid-treated product of Scarinaceae.
<7> The product according to <6>, wherein the strong acid-treated product is obtained by applying a strong acid aqueous solution having a concentration of 0.01 mol / L to 4 mol / L to ginseng and performing a hydrolysis treatment in the presence of a lower alcohol. It is a muscle bulking agent.
<8> A food or drink comprising the muscle bulking agent according to any one of <1> to <7>.

  The muscle bulking agent of the present invention and the muscle bulking agent at the time of exercise combination have an excellent muscle weight-increasing action and a muscle weight-increasing action at the time of exercise combination, and do not require a special exercise load such as resistance exercise. There is little risk and can effectively increase muscle mass. Furthermore, since the muscle bulking agent and the muscle bulking agent used in combination with exercise are natural products and have high safety, they can be suitably used for food and drink.

Claims (7)

  A muscle bulking agent comprising at least one of panaxatriol and panaxadiol.   A muscle bulking agent for combined use with exercise, comprising at least one of panaxatriol and panaxadiol.   The strength-increasing agent for combined exercise according to claim 2, wherein the intensity of exercise used in combination is 3 to 6 mets.   The muscle bulking agent according to any one of claims 1 to 3, which has an action of increasing at least one skeletal muscle sarcomere constituting protein selected from actin, myosin, thrombomyosin, and thrombonin.   The muscle bulking agent according to any one of claims 1 to 3, which has a gene expression enhancing action of at least one skeletal muscle sarcomere constituting protein selected from actin, myosin, thrombomyosin, and thrombonin.   The muscle bulking agent according to any one of claims 1 to 5, wherein at least one of panaxatriol and panaxadiol is contained in a strong acid-treated product of Scarabae ginseng. A food and drink for increasing muscle mass, comprising the muscle extender according to any one of claims 1 to 6.